Overview / Abstract: |
Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now. STATEMENT OF NEED Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin lymphoma that comprises approximately 5% of all lymphomas.Compared with patients who have other aggressive lymphomas, patients with MCL often do not respond as well to treatment (ACS, 2019).Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 4 and 5 years (LLS, 2021). Though there are several effective options, there is no currently accepted standard of care for frontline treatment of MCL (Hanel & Epperla, 2020). Selecting treatments for relapsed/refractory disease is complicated by multiple factors individual to the patient (Cortelazzo et al 2020). In order to select optimal treatments for MCL, it is vital that clinicians be familiar with the latest research. In this activity, John P. Leonard, MD, will discuss the latest research into prognostic markers of MCL, the efficacy and safety of novel therapeutic strategies, and approaches to optimize tolerability of treatments. TARGET AUDIENCE Hematologist/oncologists, hematology/oncology fellows, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with hematologic malignancies. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to |
Expiration |
Feb 14, 2023 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physical Therapy CE, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.0 CME | 1.0 NPCD | 1.0 CPE | MOC | ILNA |
Accreditation |
ACCME, ANCC, ONCC, ACPE |
Presenters / Authors / Faculty |
John Leonard, MD |
Activity Specialities / Related Topics |
Hematology, Oncology / Cancer / Radiation Therapy, Pharmacology |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from BeiGene, Bristol Myers Squibb, Merck, and Seagen. |
Keywords / Search Terms |
i3 Health i3 health, lung cancer, mantle cell lymphoma, lymphoma, MCL, hematology, CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD, CME ,Free CE CME, Free CE CME, ANCC Free CE CME Free CE CME Free CE CME |